Market Cap
$1.4B
OMER
OMEROS CORP
$18.71 ▲ +1.30%
Prev close $18.47Market cap$1.4B
ConsensusBuy
12-mo target$27.50 (+47.0%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (4 insiders)High Impact Filing (9/10)22 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on OMER right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (70%)
Inst. Holders
50 funds
Inst. Value
$303.5M
Inst. Activity
22 buys / 10 sells
Insider Activity
$0.00 buy / $2.3M sell
Insider Net $
-$2.3M
Social Sentiment
69° Warm
SEC Reports
10
Price chart 30d -0.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 Insider
Borges David J. acquired via exercise 10,000 shares
VP, Finance & CAO @ $15.58 ($155.8K)
Sep 23, 2026 Insider
Borges David J. sold 10,000 shares
VP, Finance & CAO @ $20.95 ($209.5K)
Sep 22, 2026 Insider
Borges David J. sold 10,000 shares
VP, Finance & CAO @ $20.95 ($209.5K)
Sep 15, 2026 short_volume
Sep 2, 2026 SEC Short Volume: OMER — 55.7% short (0.4M / 0.6M)
Short: 359,219 | Exempt: 1 | TRF Vol: 644,410 | Short Ratio: 55.7% | Off-exchange volume (dark pool
Three OMER insiders (VP/General Counsel, Director, VP Finance) sold a combined ~$578K in open-market shares over a week,
CLUSTER — Impact 2/10
Three OMER insiders, including two directors and the VP of Finance, sold a total of ~$387K in open-market shares over a
CLUSTER — Impact 5/10
Two insiders at Omeros (VP of Finance and a Director) sold a combined $466K in open-market shares over two days, followi
CLUSTER — Impact 3/10
Jun 30, 2026 Inst.
UBS Group AG — ADD
3,148,384 shares ($29.9M)
Analyst ratings buy % -4.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
70% rate it Buy or better · 10 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 22, 2026 | Cantor Fitzgerald | UPGRADE | Overweight | 49% |
| Jun 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Aug 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Jul 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Jun 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| May 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% |
Price targets
Where 2 covering analysts think OMER trades over the next 12 months.
$27.50 +47.0% upside Strong Buy
Current$18.71 Low$22.00 Median$27.50 High$33.00 2 analysts
$22.00$33.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Social media sentiment mood +16.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
69°
Warm
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 3 bullish, 0 bearish, 1 mixed, 6 neutral · avg impact 4.5/10.
NEUTRALCLUSTER2/10
Three OMER insiders (VP/General Counsel, Director, VP Finance) sold a combined ~$578K in open-market
Sep 2, 2026
NEUTRALCLUSTER5/10
Three OMER insiders, including two directors and the VP of Finance, sold a total of ~$387K in open-m
Aug 29, 2026
NEUTRALCLUSTER3/10
Two insiders at Omeros (VP of Finance and a Director) sold a combined $466K in open-market shares ov
Aug 25, 2026
NEUTRALCLUSTER2/10
Two OMER insiders sold a combined $362K in open-market sales over a 7-day window, with Director Thom
Aug 21, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 15, 2026
short_volume
Short Volume: OMER — 55.7% short (0.4M / 0.6M)
Short: 359,219 | Exempt: 1 | TRF Vol: 644,410 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
Clinical Trial
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Sep 8, 2026
clinical_trial_readout
T-90d Trial Readout: OMS906 study drug (Phase 2)
Trial: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Sponsor: Omeros Corporation Phase: Phase 2 | Statu
Sep 7, 2026
clinical_trial_readout
T-90d Trial Readout: OMS906 study drug (Phase 2)
Trial: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Sponsor: Omeros Corporation Phase: Phase 2 | Statu
Sep 2, 2026
clinical_trial_readout
T-90d Trial Readout: OMS906 study drug (Phase 2)
Trial: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Sponsor: Omeros Corporation Phase: Phase 2 | Statu
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.02 | $-0.05–$0.01 | 93.8% | +20.0% | — | $0.0B | 2 |
| Next Q | $0.07 | $-0.09–$0.22 | -97.9% | +44.4% | — | $0.1B | 2 |
| Current FY | $0.69 | $0.50–$0.88 | -67.1% | +4.5% | — | $0.1B | 2 |
| Next FY | $1.23 | $0.24–$2.22 | 78.3% | +7.4% | — | $0.2B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.020 | — |
| 7d ago | $-0.025 | +0.005 |
| 30d ago | $-0.025 | +0.005 |
| 60d ago | $-0.310 | +0.290 |
| 90d ago | $-0.270 | +0.250 |
Institutional ownership
Which big funds own OMER (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $303.5M total value (31,903,255 shares) as of 2026-Q2. Top holders: BlackRock,, UBS, VANGUARD. Net buying activity: 22 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 6,044,633 | $57.5M | 18.9% | — |
| UBS Group AG | 3,148,384 | $29.9M | 9.9% | ADD +34.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,072,050 | $29.2M | 9.6% | — |
| STATE STREET CORP | 2,319,906 | $22.1M | 7.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,914,460 | $18.2M | 6.0% | — |
| STIFEL FINANCIAL CORP | 1,836,925 | $17.5M | 5.8% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 971,300 | $9.2M | 3.0% | TRIM -33.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 962,828 | $9.2M | 3.0% | ADD +34.0% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 918,700 | $8.7M | 2.9% | TRIM -33.0% |
| Invesco Ltd. | 751,771 | $7.1M | 2.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | ADD | 2,340,731 | 3,148,384 | +34.5% | $29.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 718,675 | 962,828 | +34.0% | $9.2M |
| NORTHERN TRUST CORP | ADD | 563,867 | 727,348 | +29.0% | $6.9M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | 485,030 | 325,194 | -33.0% | $3.1M |
| WELLS FARGO & COMPANY/MN | ADD | 118,343 | 156,889 | +32.6% | $1.5M |
| MML INVESTORS SERVICES, LLC | DOUBLED | 57,675 | 118,175 | +104.9% | $1.1M |
| Brevan Howard Capital Management LP | ADD | 51,163 | 98,047 | +91.6% | $932.4K |
| CITADEL ADVISORS LLC | TRIM | 260,048 | 85,594 | -67.1% | $814.0K |
| Quantinno Capital Management LP | ADD | 61,541 | 83,786 | +36.1% | $796.8K |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 29,083 | 83,558 | +187.3% | $794.6K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 40 transactions. Net -$2.3M — $0.00 bought, $2.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Borges David J. | VP, Finance & CAO | EXERCISE | 10,000 | $15.58 | $155.8K |
| Sep 23, 2026 | Borges David J. | VP, Finance & CAO | SELL | 10,000 | $20.95 | $209.5K |
| Sep 22, 2026 | Borges David J. | VP, Finance & CAO | SELL | 10,000 | $20.95 | $209.5K |
| Sep 22, 2026 | Borges David J. | VP, Finance & CAO | EXERCISE | 5,000 | $3.93 | $19.6K |
| Sep 22, 2026 | Borges David J. | VP, Finance & CAO | EXERCISE | 5,000 | $2.94 | $14.7K |
| Aug 31, 2026 | Cancelmo Peter B | VP, General Counsel | EXERCISE | 25,000 | $2.94 | $73.5K |
| Aug 31, 2026 | Cancelmo Peter B | VP, General Counsel | SELL | 25,000 | $18.54 | $463.5K |
| Aug 28, 2026 | Cancelmo Peter B | VP, General Counsel | SELL | 25,000 | $18.65 | $466.1K |
| Aug 28, 2026 | Cancelmo Peter B | VP, General Counsel | EXERCISE | 25,000 | $2.94 | $73.5K |
| Aug 27, 2026 | HANISH ARNOLD C | Director | SELL | 5,000 | $19.02 | $95.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for OMER.
Shares short
12,491,576
Settlement Sep 15, 2026
Change vs prior
-2.1%
Semi-monthly cycle
Days to cover
9.3
At avg daily volume
Of shares outstanding
≈17.3%
Estimate — not % of float
All OMER filing & press-release reports (10)
- CLUSTER reportSep 2, 2026
- CLUSTER reportAug 29, 2026
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 21, 2026
- 8-K reportJul 20, 2026
- 8-K reportJul 6, 2026
- 8-K reportJun 18, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 13, 2026
- 8-K reportApr 21, 2026